الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
This study aims to compare the compliance of patients with chronic viral hepatitis (C) to treatment with (sofosbuvir + daclatacavir) with or without addition of ribavirin and to identify the reasons for non-compliance. The study was carried out on two groups, each consisting of 184 cases reported to the Mansoura Specialized Medical Hospital (Virology Outpatient Clinic). Of the world population, 2-3% are infected with hepatitis C virus, and there are more than 350,000 deaths annually as a result of illnesses related to the virus (C) such as cirrhosis and liver cancer. The rate of spread of the virus varies from one country to another, so that the rate of spread ranges from 1 to 10% depending on the specific circumstances of each country. Unlike developed countries, the spread of the virus increases in developing countries - usually - as a result of exposure to contaminated blood, whether while receiving medical service or through community interaction . In 2011, the new era of direct-acting antivirals (DAAs) begins. Dual therapy of peg-IFN and RBV is no longer the SOC for HCV. The addition of a DAA to peg-IFN/RBV nearly doubles the chances of response to treatment at the cost of increased toxicity. Treatment of HCV infection has progressed significantly since the approval of DAAs in 2014 and the following availability of interferon (IFN)-free, DAAs therapies. These programs have given promising results due to the strength of these drugs, pangenotypic coverage with no resistance, thus paving the way for IFN-free, oral, once-daily regimens, which opens the way globally to completely eliminate HCV in the near future. Patients’ adherence to treatment is important for achieving the maximum rate of SVR, avoiding treatment failure and / or resistance to the drugs used. Overall adherence was very high, with an average of 99% of the doses of antiviral drugs taken during the prescribed treatment period.